9 completed, 2 recruiting, 2 unknown, 1 not yet recruiting. 15 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 15 | Completed 9, Recruiting 2, Unknown 2, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 5 | Completed 4, Unknown 1 |
Follow siltuximab: new trials by email Literature Review of siltuximab trials Research Report on siltuximab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001) MK-6255, CD8 PET Tracer, Acetaminophen - Ovarian Neoplasms, Endometrial Neoplasms | Phase 1 | Not yet recruiting | Merck Sharp & Dohme LLC | 80 | 2026-11-13 | 2026-10-13 |
| A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation Siltuximab, Placebo - Antibody Mediated Rejection of Lung Transplant | Phase 1 | Recruiting | Washington University School of Medicine | 30 | 2025-11-06 | 2026-08-27 |
| Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab Siltuximab, Epcoritamab, Gemcitabine and oxaliplatin - Non-Hodgkin Lymphoma, Cytokine Release Syndrome | Phase 1 | Recruiting | Taylor Brooks | 20 | 2025-01-14 | 2026-06-25 |
| Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAM Siltuximab - Acute Myeloid Leukemia (AML) | Phase 1 | Unknown | Nantes University Hospital | 12 | 2023-03-16 | 2023-04-06 |
| Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma Biospecimen Collection, Computed Tomography, Positron Emission Tomography - Non-Hodgkin Lymphoma | Phase 1 | Completed | Timothy Voorhees | 11 | 2023-01-31 | 2025-01-31 |
| Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer Siltuximab, Spartalizumab - Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 | Phase 1 / Phase 2 | Completed | Emory University | 35 | 2020-01-17 | 2025-08-22 |
| Siltuximab in Schizophrenia Siltuximab, normal saline - Schizophrenia, Psychotic Disorders | Phase 1 / Phase 2 | Unknown | Brian Miller | 30 | 2016-05-01 | 2023-07-21 |
| Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) Lenalidomide, Bortezomib, Siltuximab - Myeloma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 14 | 2012-05-01 | 2015-06-19 |
| A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma Siltuximab - Multiple Myeloma | Phase 1 | Terminated | Janssen Pharmaceutical K.K. | 9 | 2011-01-01 | 2014-05-19 |
| A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma Siltuximab - Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma | Phase 1 | Completed | Janssen Research & Development, LLC | 30 | 2010-10-01 | 2015-01-19 |
| A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors CNTO 328; Anti-interleukin-6 monoclonal antibody - Ovarian Neoplasms, Pancreatic Neoplasms | Phase 1 / Phase 2 | Completed | Centocor, Inc. | 84 | 2009-03-01 | 2014-05-14 |
| A Study to Assess the Safety and Pharmacokinetics of a Single Intravenous Administration of CNTO 328 Derived From 2 Different Cell Lines in Healthy Participants CNTO 328 (Sp2/0-derived), CNTO 328 (CHO-derived), Placebo - Healthy | Phase 1 | Completed | Centocor, Inc. | 145 | 2008-06-01 | 2015-02-05 |
| A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer CNTO 328, Docetaxel - Prostatic Neoplasms | Phase 1 | Completed | Centocor, Inc. | 40 | 2005-09-01 | 2014-05-26 |
| A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease CNTO 328 - Lymphoma, Non-Hodgkin, Multiple Myeloma | Phase 1 | Completed | Centocor, Inc. | 67 | 2005-05-01 | 2014-07-01 |
| A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma CNTO 328 - Carcinoma, Renal Cell | Phase 1 / Phase 2 | Completed | Centocor, Inc. | 68 | 2003-08-01 | 2014-07-03 |
Multiple Myeloma (4) · Lymphoma, Non-Hodgkin (3) · Neoplasms, Plasma Cell (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Carcinoma, Renal Cell (1) · Castleman Disease (1) · Colorectal Neoplasms (1) · Cytokine Release Syndrome (1) · Endometrial Neoplasms (1) · Head and Neck Neoplasms (1) · Inflammation (1) · Leukemia, Myeloid, Acute (1) · Lung Neoplasms (1) · Monoclonal Gammopathy of Undetermined Significance (1)
Centocor, Inc. (5) · Brian Miller (1) · Emory University (1) · Janssen Pharmaceutical K.K. (1) · Janssen Research & Development, LLC (1) · M.D. Anderson Cancer Center (1) · Merck Sharp & Dohme LLC (1) · Nantes University Hospital (1) · Taylor Brooks (1) · Timothy Voorhees (1) · Washington University School of Medicine (1)
United States (11) · France (3) · Belgium (2) · United Kingdom (2) · Czechia (1) · Japan (1) · Netherlands (1) · Russia (1) · Spain (1)
Derek Byers, MD, PhD (1) · Jatin J. Shah, MD (1) · Olatunji Alese, MD (1) · Ramsey Hachem, MD (1) · Taylor Brooks, MD (1) · Timothy J Voorhees, MD, MSCR (1)
2008 (1), P30CA138292 (1), R61HL169189 (1)